Healthcare tech company Omnicell (NASDAQ: OMCL) will be announcing earnings results tomorrow morning. Here’s what to expect.

Omnicell beat analysts’ revenue expectations by 2.2% last quarter, reporting revenues of $306.9 million, up 18.6% year on year. It was a slower quarter for the company, with EBITDA guidance for next quarter missing analysts’ expectations.

Is Omnicell a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Omnicell’s revenue to grow 5.6% year on year to $260 million, a reversal from the 15.3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.20 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Omnicell has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Omnicell’s peers in the healthcare technology segment, only Tandem Diabetes has reported results so far. It beat analysts’ revenue estimates by 6.8%, delivering year-on-year sales growth of 22.3%. The stock traded up 18.8% on the results.

There has been positive sentiment among investors in the healthcare technology segment, with share prices up 4.9% on average over the last month. Omnicell is up 1.2% during the same time and is heading into earnings with an average analyst price target of $50.71 (compared to the current share price of $31.99).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.